We thank Fernandez-Prado et al1 for their perspective on the CITRINE study2 of patients with type 2 diabetes and hyperuricaemia. They questioned the safety of combining verinurad, a potent urate transporter 1 (URAT1) inhibitor, with the xanthine oxidase (XO) inhibitor febuxostat.They imply that verinurad-treated patients sustained more rapid eGFR deterioration and discontinued treatment for excessive loss of eGFR more frequently than with placebo.